Nucana Plc  (NCNA)
Other Ticker:  
Price: $3.7750 $-0.02 -0.396%
Day's High: $3.82 Week Perf: 2020.79 %
Day's Low: $ 3.40 30 Day Perf: -58.86 %
Volume (M): 33 52 Wk High: $ 23.75
Volume (M$): $ 123 52 Wk Avg: $13.51
Open: $3.70 52 Wk Low: $0.18

 Market Capitalization (Millions $) 198
 Shares Outstanding (Millions) 52
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 60
 Capital Exp. (TTM) (Millions $) 0

Nucana Plc
Nucana Plc is a clinical-stage biopharmaceutical company that develops and commercializes innovative oncology treatments. The company focuses on developing proprietary medicines based on its ProTide technology, which enables the potent transformation of nucleoside analogs into novel prodrugs. These prodrugs aim to improve the therapeutic index of cancer treatments by increasing their efficacy and reducing toxicities. Nucana's lead product candidate, Acelarin, is currently being evaluated in clinical trials for multiple cancer indications, including colorectal and ovarian cancers. The company is committed to advancing the field of oncology and improving patient outcomes through the development of novel and targeted therapies.

   Company Address: NuCana plc Edinburgh 0
   Company Phone Number: 357 1111   Stock Exchange / Ticker: NASDAQ NCNA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report


NuCana plc Implements ADS Ratio Change, Offering Greater Liquidity and Potential Upsides for Shareholders Amidst Stock Performance Challenges

Published Tue, Apr 16 2024 12:01 PM UTC

NuCana plc, a pharmaceutical company based in Edinburgh, United Kingdom, recently announced a significant change that will have a profound impact on its shareholders. The company has successfully altered the ratio of its American Depositary Shares (ADSs) to ordinary shares, moving from the existing one ADS representing one ordinary share to one ADS representing twenty-five o...


NuCana plc Restructures ADS Ratio: Impact on Shareholders and Market Performance

Published Wed, Mar 27 2024 8:30 PM UTC

NuCana plc Announces Change in ADS Ratio: Impact on Shareholders and Market Performance
EDINBURGH, United Kingdom, March 27, 2024 - NuCana plc (NASDAQ: NCNA) recently revealed its plans to adjust the ratio of its American Depository Shares (ADSs) to ordinary shares, from one ADS representing one ordinary share to one ADS representing twenty-five ordinary shares. This cha...

Earnings announcement

NuCana's NUC-3373 Shows Promise in Second-line Colorectal Cancer Treatment, Ignites Hope in Oncology Community

Published Fri, Oct 13 2023 4:30 PM UTC

NUC-3373 Demonstrates Encouraging Results in Colorectal Cancer Treatment
In a recent press release, NuCana Plc presented promising data on its investigational drug NUC-3373 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. The results showcased the drug's potential in the treatment of second-line colorectal cancer, highligh...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com